Short answer
Theravance Biopharma, Inc. (TBPH) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $21M (down 20.9% year over year) with net income of −$6M.
Q2 2026 key financials · XBRL
- Revenue
- $21M
- −20.9% YoY · +17.1% QoQ
- Net income
- −$6M
- −110.8% YoY · −19.6% QoQ
- Operating margin
- -39.9%
- EPS (diluted)
- −$0.11
- −110.2% YoY · −10.0% QoQ
Source: XBRL data from the Theravance Biopharma, Inc. (TBPH) Q2 2026 10-Q on SEC EDGAR. USD.
Theravance Biopharma, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- YUPELRI net sales $70.7M, up 7% YoY from $66.3M
- Theravance implied YUPELRI share $24.7M, up 7% YoY from $23.2M
- Best-performing product line YUPELRI, with 7% YoY growth
- Restructuring targeting approximately 60% lower operating expenses versus $111.1M in 2025
- Merger with Zymeworks expected in second half of 2026; CYPRESS program winding down after missed endpoint
Risk Factors
- Merger completion risk triggered by June 28, 2026 Zymeworks agreement, requiring two-thirds shareholder approval and Hart-Scott-Rodino clearance
- Merger termination fee of $32.5 million, consuming cash otherwise available for corporate purposes
- Regulatory compliance risk from FDA oversight, with noncompliance potentially triggering penalties and commercialization restrictions
- YUPELRI market risk from evolved channel mix and lower realized net price
- Profitability risk with six-month 2026 net loss of $10.8 million and accumulated deficit of $870.5 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Theravance Biopharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.